Growth • Biomm

BIOM3

Biomm is a Brazilian biopharmaceutical company focused on the development, production and sale of biotech and biosimilar drugs in the domestic market. Its main therapeutic focus is treating diabetes, with a portfolio that includes human insulin and insulin analogs, such as glargine. The company's business model is based on strategic partnerships with international pharmaceutical companies to license and introduce new technologies and products in Brazil. A central pillar of its strategy is to build its own plant in Nova Lima (MG), which will allow local insulin production. Biomm markets its products both in the private market, through pharmacies, and in the public sector, through government tenders.